Astellas Gets Europe Okay For AML Drug Xospata
Pulls Further Ahead Of Daiichi Sankyo's Rival FLT3 Inhibitor
Executive SummaryFollowing green lights in the US and Japan, Xospata has been approved for relapsed or refractory FLT3-positive acute myeloid leukemia. Getting first-line approval is the next step.
You may also be interested in...
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
Seven new products, including the world’s first ever Ebola vaccine, are on track to receive EU-wide approval. Meanwhile, two drugs have failed to make the grade.
Japan grants first approval worldwide for Daiichi Sankyo's oral FLT3 inhibitor, marking progress for Japanese firm's global oncology ambitions.